Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments (2019 - 2026)

Intellia Therapeutics (NTLA) has reported Change in Acquisitions & Divestments for 8 consecutive years, with $113.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 36.42% year-over-year to $113.4 million; the TTM figure through Mar 2026 stood at $486.8 million (down 50.19% YoY), while the FY2025 annual figure was $551.7 million, down 48.29% from the prior year.
• Change in Acquisitions & Divestments grew to $113.4 million in Q1 2026 per NTLA's latest filing, from $94.7 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $321.6 million in Q4 2024 and bottomed at $93.7 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $192.2 million across 5 years, with a median of $199.7 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments surged 181.24% — and 2025, when it sank 70.55%.
• Intellia Therapeutics' Change in Acquisitions & Divestments stood at $210.2 million in 2022, then slipped by 6.17% to $197.2 million in 2023, then jumped by 63.08% to $321.6 million in 2024, then tumbled by 70.55% to $94.7 million in 2025, then increased by 19.69% to $113.4 million in 2026.
• Business Quant data shows NTLA's Change in Acquisitions & Divestments at $113.4 million in Q1 2026, $94.7 million in Q4 2025, and $115.9 million in Q3 2025.